Articles with "ceritinib" as a keyword



Photo from wikipedia

Ceritinib-Induced Organizing Pneumonia in Lung Cancer: A Retrospective Analysis

Sign Up to like & get
recommendations!
Published in 2020 at "Targeted Oncology"

DOI: 10.1007/s11523-020-00733-x

Abstract: Ceritinib is a potent selective ALK inhibitor with a manageable safety profile. In anecdotal reports, ceritinib was associated with organizing pneumonia (OP), which could be confused with disease progression. We aimed to delineate the characteristics… read more here.

Keywords: organizing pneumonia; ceritinib; lung cancer;
Photo from wikipedia

Ceritinib in patients with advanced, crizotinib-treated, anaplastic lymphoma kinase-rearranged NSCLC: Japanese subset

Sign Up to like & get
recommendations!
Published in 2017 at "Japanese Journal of Clinical Oncology"

DOI: 10.1093/jjco/hyx045

Abstract: Introduction Anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer is sensitive to tyrosine kinase inhibitors; however, resistance can develop. Data are presented from the phase II trial (ASCEND-2) evaluating efficacy and safety in a subset… read more here.

Keywords: lymphoma kinase; rearranged non; kinase; anaplastic lymphoma ... See more keywords
Photo from wikipedia

Neoadjuvant ceritinib treatment achieved pathological complete response in patients with anaplastic lymphoma kinase positive stage IIIA-N2 non-small cell lung cancer

Sign Up to like & get
recommendations!
Published in 2023 at "Chinese Medical Journal"

DOI: 10.1097/cm9.0000000000002403

Abstract: To the Editor: Anaplastic lymphoma kinase (ALK) fusion oncogene occurs in 3% to 7% of patients with non-small cell lung cancer (NSCLC), with the most common companion being echinoderm microtubule-associated protein-like 4. [1] Ceritinib is… read more here.

Keywords: lymphoma kinase; ceritinib; non small; anaplastic lymphoma ... See more keywords
Photo from wikipedia

Excellent response of lung adenocarcinoma harboring a rare SLC8A1 downstream intergenic region ALK fusion to ceritinib treatment: A case report

Sign Up to like & get
recommendations!
Published in 2022 at "Medicine"

DOI: 10.1097/md.0000000000030255

Abstract: Rationale: Anaplastic lymphoma kinase (ALK) gene fusion, an important driver gene alteration leading to the development of lung cancer, occurs in 5% of nonsmall cell lung cancer (NSCLC) cases in China. In addition to echinoderm… read more here.

Keywords: fusion; ceritinib; lung; slc8a1 downstream ... See more keywords
Photo by susangkomen3day from unsplash

Ceritinib‐associated hyperglycemia in the Japanese Adverse Drug Event Report Database

Sign Up to like & get
recommendations!
Published in 2019 at "Journal of Diabetes Investigation"

DOI: 10.1111/jdi.13168

Abstract: Genetic rearrangements of anaplastic lymphoma kinase contribute to the pathogenesis of non‐small‐cell lung cancer; the anaplastic lymphoma kinase inhibitor, ceritinib, is widely used, as it is effective even in patients with non‐small‐cell lung cancer resistant… read more here.

Keywords: japanese adverse; drug event; report database; ceritinib ... See more keywords
Photo by cdc from unsplash

Acute Interstitial Lung Disease Induced by Rechallenge with Ceritinib

Sign Up to like & get
recommendations!
Published in 2019 at "Internal Medicine"

DOI: 10.2169/internalmedicine.2597-18

Abstract: A 40-year-old Japanese man with advanced pulmonary adenocarcinoma harboring anaplastic lymphoma kinase (ALK)-rearranged was administered the selective ALK inhibitor ceritinib as a third-line treatment and continued treatment for nine months. After fourth-line treatment, we performed… read more here.

Keywords: treatment; lung disease; ceritinib; interstitial lung ... See more keywords
Photo from wikipedia

Efficacy of Ceritinib After Alectinib for ALK-positive Non-small Cell Lung Cancer

Sign Up to like & get
recommendations!
Published in 2018 at "In Vivo"

DOI: 10.21873/invivo.11418

Abstract: Background: Alectinib is a new standard treatment for treatment-naïve anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC); however, resistance ultimately develops in almost all patients, and data regarding the efficiency of ceritinib for such… read more here.

Keywords: alk positive; ceritinib; non small; positive non ... See more keywords
Photo from wikipedia

Ceritinib compassionate use for patients with crizotinib-refractory, anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer.

Sign Up to like & get
recommendations!
Published in 2018 at "Future oncology"

DOI: 10.2217/fon-2017-0441

Abstract: AIM Ceritinib was evaluated within a compassionate use program of Italian patients. PATIENTS & METHODS 70 patients with anaplastic lymphoma kinase-positive crizotinib-refractory advanced non-small-cell lung cancer received ceritinib. RESULTS Overall response was 40.6%, median progression-free… read more here.

Keywords: lymphoma kinase; compassionate use; anaplastic lymphoma; ceritinib ... See more keywords
Photo by 20164rhodi from unsplash

Ceritinib (LDK378) prevents bone loss via suppressing Akt and NF-κB-induced osteoclast formation

Sign Up to like & get
recommendations!
Published in 2022 at "Frontiers in Endocrinology"

DOI: 10.3389/fendo.2022.939959

Abstract: Background Ceritinib is used for the treatment of patients with anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer (NSCLC), who are at the risk of developing bone metastasis. During bone metastasis, tumor cells release factors… read more here.

Keywords: bone loss; effect ceritinib; osteoclast formation; ceritinib ... See more keywords
Photo from wikipedia

Ceritinib in anaplastic lymphoma kinase-positive nonsmall cell lung cancer among patients who were previously exposed to crizotinib: Experience from the Indian subcontinent.

Sign Up to like & get
recommendations!
Published in 2017 at "Indian journal of cancer"

DOI: 10.4103/ijc.ijc_186_17

Abstract: Ceritinib is a novel ALK inhibitor approved for advanced stage NSCLC with ALK gene rearrangement, progressed and/or intolerant to crizotinib. 13 patients were included in our study who received ceritinib. Majority of them were women… read more here.

Keywords: lymphoma kinase; anaplastic lymphoma; crizotinib; ceritinib ... See more keywords